For colon cancer patients, SFRP2 hypermethylation patients and co-hypermethylation of SFRP1 and SFRP2 patients had a significantly favorable outcome through multivariate Cox regression, PS-1 and PS-2 analysis. This evidence concerns the gene SFRP2 and colonic neoplasm.